West Pharma CEO Eric Green to retire after 11 years at the helm

Core Viewpoint - West Pharmaceutical Services Inc's CEO Eric Green announced his retirement after 11 years, with a transition expected in the second half of 2026 as the company seeks a successor [1] Company Leadership Transition - Eric Green has served as CEO since 2015 and became board chair in 2022, stating it is time for new leadership [1] - An executive search firm has been hired to assist in finding Green's successor [1] Company Performance - Under Green's leadership, West Pharmaceutical more than doubled its sales and achieved a total shareholder return of approximately 350% [1] Market Demand - The company noted that demand for GLP1 therapies, which are used in diabetes and obesity treatments, is expected to continue growing in 2026, albeit at a slower pace than in 2025 [1] - GLP1 drugs represent one of the fastest-growing segments in the pharmaceutical market, necessitating the precision delivery components provided by West [1] Financial Outlook - West reaffirmed its annual financial forecast issued in February, indicating confidence in its future performance [1]